Cargando…
Determination of Optimal Vitamin D Dosage in Children with Cholestasis
BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283200/ https://www.ncbi.nlm.nih.gov/pubmed/37344793 http://dx.doi.org/10.1186/s12887-023-04113-y |
_version_ | 1785061258618208256 |
---|---|
author | Chongthavornvasana, Sirada Lertudomphonwanit, Chatmanee Mahachoklertwattana, Pat Korwutthikulrangsri, Manassawee |
author_facet | Chongthavornvasana, Sirada Lertudomphonwanit, Chatmanee Mahachoklertwattana, Pat Korwutthikulrangsri, Manassawee |
author_sort | Chongthavornvasana, Sirada |
collection | PubMed |
description | BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without cholestasis is used. However, data on high-dose vitamin D treatment in patients with cholestasis are limited. METHODS: This study is a prospective study that included pediatric patients with cholestasis (serum direct bilirubin > 1 mg/dL) who had vitamin D deficiency (serum 25-hydroxyvitamin D, 25-OHD, < 20 ng/mL). In Phase 1, single-day oral loading of 300,000 IU (or 600,000 IU if weight ≥ 20 kg) of vitamin D2 was administered, followed by an additional loading if serum 25-OHD < 30 ng/mL, and 4-week continuation of treatment using a vitamin D2 dose calculated based on the increment of 25-OHD after first loading. In Phase 2, oral vitamin D2 (200,000 IU/day) was administered for 12 days, followed by 400,000 IU/day of vitamin D2 orally for another 8 weeks if serum 25-OHD < 30 ng/mL. RESULTS: Phase 1: Seven patients were enrolled. Three out of seven patients had a moderate increase in serum 25-OHD after loading (up to 20.3–27.2 ng/mL). These patients had conditions with partially preserved bile flow. The remaining four patients, who had biliary atresia with failed or no Kasai operation, had low increments of serum 25-OHD. Phase 2: Eleven patients were enrolled. Eight out of 11 patients had a moderate increase in serum 25-OHD after 200,000 IU/day of vitamin D2 for 12 days. Serum 25-OHD continued increasing after administering 400,000 IU/day of vitamin D2 for another 8 weeks, with maximal serum 25-OHD of 15.7–22.8 ng/mL. CONCLUSION: Very high doses of vitamin D2 (200,000 and 400,000 IU/day) partly overcame poor intestinal vitamin D absorption and resulted in moderate increases in serum 25-OHD in pediatric patients with cholestasis, particularly when cholestasis was caused by uncorrectable bile duct obstruction. |
format | Online Article Text |
id | pubmed-10283200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102832002023-06-22 Determination of Optimal Vitamin D Dosage in Children with Cholestasis Chongthavornvasana, Sirada Lertudomphonwanit, Chatmanee Mahachoklertwattana, Pat Korwutthikulrangsri, Manassawee BMC Pediatr Research BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without cholestasis is used. However, data on high-dose vitamin D treatment in patients with cholestasis are limited. METHODS: This study is a prospective study that included pediatric patients with cholestasis (serum direct bilirubin > 1 mg/dL) who had vitamin D deficiency (serum 25-hydroxyvitamin D, 25-OHD, < 20 ng/mL). In Phase 1, single-day oral loading of 300,000 IU (or 600,000 IU if weight ≥ 20 kg) of vitamin D2 was administered, followed by an additional loading if serum 25-OHD < 30 ng/mL, and 4-week continuation of treatment using a vitamin D2 dose calculated based on the increment of 25-OHD after first loading. In Phase 2, oral vitamin D2 (200,000 IU/day) was administered for 12 days, followed by 400,000 IU/day of vitamin D2 orally for another 8 weeks if serum 25-OHD < 30 ng/mL. RESULTS: Phase 1: Seven patients were enrolled. Three out of seven patients had a moderate increase in serum 25-OHD after loading (up to 20.3–27.2 ng/mL). These patients had conditions with partially preserved bile flow. The remaining four patients, who had biliary atresia with failed or no Kasai operation, had low increments of serum 25-OHD. Phase 2: Eleven patients were enrolled. Eight out of 11 patients had a moderate increase in serum 25-OHD after 200,000 IU/day of vitamin D2 for 12 days. Serum 25-OHD continued increasing after administering 400,000 IU/day of vitamin D2 for another 8 weeks, with maximal serum 25-OHD of 15.7–22.8 ng/mL. CONCLUSION: Very high doses of vitamin D2 (200,000 and 400,000 IU/day) partly overcame poor intestinal vitamin D absorption and resulted in moderate increases in serum 25-OHD in pediatric patients with cholestasis, particularly when cholestasis was caused by uncorrectable bile duct obstruction. BioMed Central 2023-06-21 /pmc/articles/PMC10283200/ /pubmed/37344793 http://dx.doi.org/10.1186/s12887-023-04113-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chongthavornvasana, Sirada Lertudomphonwanit, Chatmanee Mahachoklertwattana, Pat Korwutthikulrangsri, Manassawee Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title | Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title_full | Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title_fullStr | Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title_full_unstemmed | Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title_short | Determination of Optimal Vitamin D Dosage in Children with Cholestasis |
title_sort | determination of optimal vitamin d dosage in children with cholestasis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283200/ https://www.ncbi.nlm.nih.gov/pubmed/37344793 http://dx.doi.org/10.1186/s12887-023-04113-y |
work_keys_str_mv | AT chongthavornvasanasirada determinationofoptimalvitaminddosageinchildrenwithcholestasis AT lertudomphonwanitchatmanee determinationofoptimalvitaminddosageinchildrenwithcholestasis AT mahachoklertwattanapat determinationofoptimalvitaminddosageinchildrenwithcholestasis AT korwutthikulrangsrimanassawee determinationofoptimalvitaminddosageinchildrenwithcholestasis |